This second tumor shrinkage finding could be important for the minority of patients whose metastases are only slightly too big to attempt a curative surgery.
Late last year, the drug chalked up a medical first when it became the first drug to delay the onset of bone metastases in high-risk prostate cancer patients who were failing hormone therapy.